-The Economic Times For one who had worked so closely to frame the world's largest job guarantee programme, known as the Mahatma Gandhi National Rural Employment Guarantee Act, it's not easy to see it succumb to pressure. It's no wonder that economist-cum-activist Jean Dreze will raise his voice against this, along with eminent academics such as Pranab Bardhan and Maitreesh Ghatak. Dreze says corruption related to NREGA and leakages - its...

-The Hindu Is India ready to cash in on its demographic dividend? A demographic dividend is a once-in-a-lifetime opportunity for a nation and can either make or mar its citizens' present and future. When the share of the working-age population is on a rising curve while the share of dependents (those under the age of 15 and over 60) is falling, it enables workers to save (hence savings share in GDP rises)...

-The Hindustan Times The government is gearing up for its next big mission, a Rs. 113,000-crore plan that aims to usher in a digital revolution by moving everything online, from education to public services to bureaucracy. Aptly called ‘e-kranti', it comes under the Narendra Modi government's ‘Digital India' initiative and is quite simply the world's most ambitious broadband project - but one that will have to overcome countless hurdles, big and small....

-The Hindu Reports that the National Democratic Alliance (NDA) government intends to radically restructure the Mahatma Gandhi National Rural Employment Guarantee Act (MGNREGA) have re-ignited public discussion on the scheme. Since its launch, debate on MGNREGA has been synonymous with ideological contestations on the role of the state and its welfare functions. Inevitably, the contours of the debate have been shrill, leaving little space for an evidence-based discussion on the...

-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...